[go: up one dir, main page]

CN103998598A - 用于干细胞增殖和诱导的培养基 - Google Patents

用于干细胞增殖和诱导的培养基 Download PDF

Info

Publication number
CN103998598A
CN103998598A CN201280062509.8A CN201280062509A CN103998598A CN 103998598 A CN103998598 A CN 103998598A CN 201280062509 A CN201280062509 A CN 201280062509A CN 103998598 A CN103998598 A CN 103998598A
Authority
CN
China
Prior art keywords
cell
nme7
stem cell
substratum
nme1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280062509.8A
Other languages
English (en)
Chinese (zh)
Inventor
辛西娅·巴姆达德
贝努瓦·J·斯马格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/036975 external-priority patent/WO2012154759A2/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Priority to CN201811288611.5A priority Critical patent/CN109456932A/zh
Publication of CN103998598A publication Critical patent/CN103998598A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0056—Xeno-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201280062509.8A 2011-10-17 2012-10-17 用于干细胞增殖和诱导的培养基 Pending CN103998598A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811288611.5A CN109456932A (zh) 2011-10-17 2012-10-17 用于干细胞增殖和诱导的培养基

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
US201161548199P 2011-10-17 2011-10-17
US61/548,199 2011-10-17
US201261618578P 2012-03-30 2012-03-30
US61/618,578 2012-03-30
US201261622422P 2012-04-10 2012-04-10
US61/622,422 2012-04-10
USPCT/US12/36975 2012-05-08
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants
US201261671558P 2012-07-13 2012-07-13
US201261671588P 2012-07-13 2012-07-13
US61/671,588 2012-07-13
US61/671,558 2012-07-13
US201261673617P 2012-07-19 2012-07-19
US61/673,617 2012-07-19
US201261675292P 2012-07-24 2012-07-24
US201261675264P 2012-07-24 2012-07-24
US61/675,264 2012-07-24
US61/675,292 2012-07-24
US201261677442P 2012-07-30 2012-07-30
US61/677,442 2012-07-30
US201261679021P 2012-08-02 2012-08-02
US61/679,021 2012-08-02
US201261683155P 2012-08-14 2012-08-14
US61/683,155 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US61/684,654 2012-08-17
US201261693712P 2012-08-27 2012-08-27
US61/693,712 2012-08-27
PCT/US2012/060684 WO2013059373A2 (en) 2011-10-17 2012-10-17 Media for stem cell proliferation and induction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811288611.5A Division CN109456932A (zh) 2011-10-17 2012-10-17 用于干细胞增殖和诱导的培养基

Publications (1)

Publication Number Publication Date
CN103998598A true CN103998598A (zh) 2014-08-20

Family

ID=48141618

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811288611.5A Pending CN109456932A (zh) 2011-10-17 2012-10-17 用于干细胞增殖和诱导的培养基
CN201280062509.8A Pending CN103998598A (zh) 2011-10-17 2012-10-17 用于干细胞增殖和诱导的培养基

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811288611.5A Pending CN109456932A (zh) 2011-10-17 2012-10-17 用于干细胞增殖和诱导的培养基

Country Status (8)

Country Link
US (2) US11591565B2 (ja)
EP (1) EP2768945B1 (ja)
JP (5) JP6466170B2 (ja)
CN (2) CN109456932A (ja)
AU (1) AU2012326137B2 (ja)
CA (1) CA2852244C (ja)
IL (1) IL232107B (ja)
WO (1) WO2013059373A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107920501A (zh) * 2015-07-01 2018-04-17 米纳瓦生物技术公司 基于干细胞的器官和组织的产生的方法
CN111511901A (zh) * 2017-12-06 2020-08-07 李廷福 包含作为从鸟类的蛋分离的细胞的胚盘多能干细胞、神经干细胞、胚胎成纤维细胞条件培养基作为有效成分的用于细胞增殖、皮肤再生及皱纹改善的培养基组合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126013A2 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
CA2879111A1 (en) * 2012-07-13 2014-01-16 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
WO2015023694A2 (en) * 2013-08-12 2015-02-19 Minerva Biotechnologies Corporation Method for enhancing tumor growth
KR20210107166A (ko) * 2014-04-07 2021-08-31 미네르바 바이오테크놀로지 코포레이션 항-ｎｍｅ 항체
US11746159B2 (en) * 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CA2999503A1 (en) * 2015-09-23 2017-03-30 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
WO2018047941A1 (ja) * 2016-09-08 2018-03-15 協和発酵バイオ株式会社 幹細胞培養用培地、幹細胞の培養方法、幹細胞の増殖促進剤、並びに細胞組成物およびその製造方法
WO2018071583A2 (en) * 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
AU2020219046A1 (en) 2019-02-04 2021-08-19 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
CN115103903A (zh) * 2019-09-19 2022-09-23 西北大学 用于人诱导型多能干细胞的具成本效益的培养基和操作方案
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
JP7581015B2 (ja) 2020-10-30 2024-11-12 株式会社小松製作所 データ送信システム、作業機械、および作業機械のデータ送信方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1926234A (zh) * 2003-12-05 2007-03-07 伯明翰大学 使用nm23的细胞培养,包含nm23的细胞培养基和在nm23存在下培养的细胞的治疗性用途
US20100093092A1 (en) * 2008-10-09 2010-04-15 Bamdad Cynthia C Method for inducing pluripotency in cells
WO2010144887A1 (en) * 2009-06-11 2010-12-16 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
CA2190121A1 (en) 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP4564714B2 (ja) 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
CA2459583A1 (en) 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
EP1375661A1 (en) 2002-06-17 2004-01-02 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam The role of the N-myc - nm23H1/nm23H2 - cdc42 pathway in proliferation, differentiation and treatment of cancer
EP1660535A2 (en) 2002-11-27 2006-05-31 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
EP1811844A4 (en) 2004-09-14 2009-12-02 Minerva Biotechnologies Corp METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2527365A3 (en) * 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
US8440457B2 (en) 2005-06-06 2013-05-14 Suomen Punainen Risti, Veripalvelu Method of profiling a cell population
CN101273060A (zh) 2005-06-24 2008-09-24 美国政府（由卫生和人类服务部、国立卫生研究院的部长所代表） 通过靶向肿瘤坏死因子受体的前配体装配域(plad)来缓解炎性关节炎
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2008070082A2 (en) 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2008070171A2 (en) * 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Method for identifying and manipulating cells
US8273722B2 (en) 2007-07-13 2012-09-25 Dharmacon, Inc. Enhanced biotherapeutic production using inhibitory RNA
US20110009469A1 (en) 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
WO2009075817A1 (en) * 2007-12-06 2009-06-18 Minerva Biotechnologies Corporation Method for treating cancer using interference rna
US20100278788A1 (en) * 2008-01-11 2010-11-04 Bone Therapeutics, S.A. Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors
WO2009102983A2 (en) * 2008-02-15 2009-08-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
JP5464443B2 (ja) 2008-03-31 2014-04-09 オリエンタル酵母工業株式会社 多能性幹細胞を増殖させる方法
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
WO2009152084A2 (en) 2008-06-11 2009-12-17 Cell4Vet Llc Adipose tissue-derived stem cells for veterinary use
WO2010042981A1 (en) 2008-10-14 2010-04-22 Shaun Joseph Cunningham Photo-voltaic device
CA2741090C (en) 2008-10-24 2018-10-16 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
KR20110134939A (ko) 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 유도된 다능성 줄기 세포
WO2010124143A1 (en) 2009-04-23 2010-10-28 Nevada Cancer Institute Reprogramming of somatic cells with purified proteins
EP4166652A1 (en) * 2009-11-12 2023-04-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP2582399A4 (en) * 2010-06-16 2015-04-15 Minerva Biotechnologies Corp NEW PROGRAMMING OF CANCER CELLS
EP2594644B1 (en) 2010-07-12 2016-08-10 National University Corporation Tottori University Method for preparing novel hipsc by means of mirna introduction
JP5921558B2 (ja) 2010-10-14 2016-05-24 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 心臓人工多能性幹細胞ならびに心筋の修復および再生に使用する方法
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
CA2879111A1 (en) 2012-07-13 2014-01-16 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
CN104995518A (zh) 2012-07-24 2015-10-21 米纳瓦生物技术公司 Nme变体物种表达和抑制

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1926234A (zh) * 2003-12-05 2007-03-07 伯明翰大学 使用nm23的细胞培养,包含nm23的细胞培养基和在nm23存在下培养的细胞的治疗性用途
US20100093092A1 (en) * 2008-10-09 2010-04-15 Bamdad Cynthia C Method for inducing pluripotency in cells
WO2010144887A1 (en) * 2009-06-11 2010-12-16 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107920501A (zh) * 2015-07-01 2018-04-17 米纳瓦生物技术公司 基于干细胞的器官和组织的产生的方法
CN111511901A (zh) * 2017-12-06 2020-08-07 李廷福 包含作为从鸟类的蛋分离的细胞的胚盘多能干细胞、神经干细胞、胚胎成纤维细胞条件培养基作为有效成分的用于细胞增殖、皮肤再生及皱纹改善的培养基组合物

Also Published As

Publication number Publication date
AU2012326137A1 (en) 2014-05-01
IL232107B (en) 2020-01-30
US11591565B2 (en) 2023-02-28
AU2012326137B2 (en) 2018-11-29
JP2020182483A (ja) 2020-11-12
IL232107A0 (en) 2014-05-28
JP2024038024A (ja) 2024-03-19
EP2768945B1 (en) 2022-01-05
CA2852244A1 (en) 2013-04-25
EP2768945A2 (en) 2014-08-27
CN109456932A (zh) 2019-03-12
US20230287338A1 (en) 2023-09-14
JP2022046658A (ja) 2022-03-23
JP2017074054A (ja) 2017-04-20
WO2013059373A2 (en) 2013-04-25
EP2768945A4 (en) 2015-07-29
WO2013059373A3 (en) 2013-06-20
JP2014530025A (ja) 2014-11-17
US11976295B2 (en) 2024-05-07
JP6466170B2 (ja) 2019-02-06
CA2852244C (en) 2023-10-17
US20150017726A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
CN103998598A (zh) 用于干细胞增殖和诱导的培养基
CN102272290B (zh) 用于在细胞中诱导多能性的方法
JP7501824B2 (ja) より未分化状態への細胞の誘導方法
CN103384679A (zh) 重组层粘连蛋白-521
US20240247229A1 (en) Media for stem cell proliferation and induction
Jia et al. Applications of plant-made fibroblast growth factor for human pluripotent stem cells
JP2018520682A (ja) 幹細胞に基づいた器官および組織生成の方法
WO2009055868A1 (en) Process and compositions for culturing cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140820

RJ01 Rejection of invention patent application after publication